Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Inferring B-cell derived T-cell receptor induced multi-epitope-based vaccine candidate against enterovirus 71: a reverse vaccinology approach

  • Subrat Kumar Swain (Department of Medical Research, IMS and SUM Hospital, Siksha ) ;
  • Subhasmita Panda (Department of Pediatrics, IMS and SUM Hospital, Siksha ) ;
  • Basanta Pravas Sahu (School of Biological Science, The University of Hong Kong) ;
  • Soumya Ranjan Mahapatra (School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University) ;
  • Jyotirmayee Dey (School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University) ;
  • Rachita Sarangi (Department of Pediatrics, IMS and SUM Hospital, Siksha ) ;
  • Namrata Misra (School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University)
  • Received : 2023.08.26
  • Accepted : 2024.03.30
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Enterovirus 71, a pathogen that causes hand-foot and mouth disease (HFMD) is currently regarded as an increasing neurotropic virus in Asia and can cause severe complications in pediatric patients with blister-like sores or rashes on the hand, feet, and mouth. Notwithstanding the significant burden of the disease, no authorized vaccine is available. Previously identified attenuated and inactivated vaccines are worthless over time owing to changes in the viral genome. Materials and Methods: A novel vaccine construct using B-cell derived T-cell epitopes from the virulent polyprotein found the induction of possible immune response. In order to boost the immune system, a beta-defensin 1 preproprotein adjuvant with EAAAK linker was added at the N-terminal end of the vaccine sequence. Results: The immunogenicity of the designed, refined, and verified prospective three-dimensional-structure of the multi-epitope vaccine was found to be quite high, exhibiting non-allergenic and antigenic properties. The vaccine candidates bound to toll-like receptor 3 in a molecular docking analysis, and the efficacy of the potential vaccine to generate a strong immune response was assessed through in silico immunological simulation. Conclusion: Computational analysis has shown that the proposed multi-epitope vaccine is possibly safe for use in humans and can elicit an immune response.

Keywords

Acknowledgement

We are thankful to Indian Council of Medical Research (ICMR) for providing the ICMR-RA fellowship (5/3/8/51/ITR-F/2020). Also, the authors are very much thankful to Medical Research Laboratory of Siksha "O" Anusandhan (deemed to be) University for providing laboratory facility.

References

  1. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009;10:837-52.
  2. Flower DR. Bioinformatics for vaccinology. Hoboken (NJ): John Wiley & Sons; 2008.
  3. Bourdette DN, Edmonds E, Smith C, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler 2005;11:552-61.
  4. Lopez JA, Weilenman C, Audran R, et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans: implications for vaccination strategies. Eur J Immunol 2001;31:1989-98.
  5. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
  6. Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014;14:308-18.
  7. Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LF. Immuno-pathogenesis and virus-host interactions of enterovirus 71 in patients with hand, foot and mouth disease. Front Microbiol 2017;8:2249.
  8. Lei X, Cui S, Zhao Z, Wang J. Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease. Natl Sci Rev 2015;2:268-84.
  9. Bello AM, Roshorm YM. Recent progress and advances towards developing enterovirus 71 vaccines for effective protection against human hand, foot and mouth disease (HFMD). Biologicals 2022;79:1-9.
  10. Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res 2017;6:4-14.
  11. Lu IN, Farinelle S, Sausy A, Muller CP. Identification of a CD4 T-cell epitope in the hemagglutinin stalk domain of pandemic H1N1 influenza virus and its antigen-driven TCR usage signature in BALB/c mice. Cell Mol Immunol 2017;14:511-20.
  12. He R, Yang X, Liu C, et al. Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model. Cell Mol Immunol 2018;15:815-26.
  13. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 2007;8:424.
  14. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res 2020;48:W449-54.
  15. Saha S, Raghava GP. Prediction methods for B-cell epitopes. Methods Mol Biol 2007;409:387-94.
  16. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2: a server for in silico prediction of allergens. J Mol Model 2014;20:2278.
  17. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007;8:4.
  18. Cheng J, Randall AZ, Sweredoski MJ, Baldi P. SCRATCH: a protein structure and structural feature prediction server. Nucleic Acids Res 2005;33:W72-6.
  19. Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One 2013;8:e73957.
  20. Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res 2019;47(D1):D339-43.
  21. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 2006;7:153.
  22. Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the Expasy server. In: Walker JM, editor. The proteomics protocols handbook. New York (NY): Humana Press; 2005. p. 571-607.
  23. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics 2000;16:404-5.
  24. Lee GR, Won J, Heo L, Seok C. GalaxyRefine2: simultaneous refinement of inaccurate local regions and overall protein structure. Nucleic Acids Res 2019;47:W451-5.
  25. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283-91.
  26. Craig DB, Dombkowski AA. Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins. BMC Bioinformatics 2013;14:346.
  27. Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein-protein docking. Nat Protoc 2017;12:255-78.
  28. van der Sanden S, Koopmans M, Uslu G, van der Avoort H; Dutch Working Group for Clinical Virology. Epidemiology of enterovirus 71 in the Netherlands, 1963 to 2008. J Clin Microbiol 2009;47:2826-33.
  29. Rapin N, Lund O, Bernaschi M, Castiglione F. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One 2010;5:e9862.
  30. Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007;81:9386-95.
  31. Ooi EE, Phoon MC, Ishak B, Chan SH. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis 2002;8:995-7.
  32. Van Tu P, Thao NT, Perera D, et al. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis 2007;13:1733-41.
  33. Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 2007;17:371-9.
  34. Chan YF, Sam IC, AbuBakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 2010;10:404-12.
  35. Wu SC, Liu CC, Lian WC. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 2004;22:3858-64.
  36. Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007;5:6.
  37. Murray KA, Allen T, Loh E, Machalaba C, Daszak P. Emerging viral zoonoses from wildlife associated with animal-based food systems: risks and opportunities. In: Jay-Russell M, Doyle M, editors. Food safety risks from wildlife: challenges in agriculture, conservation, and public health. Cham: Springer; 2016. p. 31-57.
  38. Ojha R, Nandani R, Prajapati VK. Contriving multiepitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein-Barr virus-associated malignancy. J Cell Physiol 2019;234:6437-48.
  39. Sharma A, Sanduja P, Anand A, et al. Advanced strategies for development of vaccines against human bacterial pathogens. World J Microbiol Biotechnol 2021;37:67.
  40. Moise L, Gutierrez A, Kibria F, et al. iVAX: an integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Hum Vaccin Immunother 2015;11:2312-21.